+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pneumococcal Testing Market - Global Forecast 2026-2032- Product Image
Pneumococcal Testing Market - Global Forecast 2026-2032- Product Image
Sale

Pneumococcal Testing Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • July 2026
  • Region: Global
  • 360iResearch™
  • ID: 5336733
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pneumococcal Testing Market is projected to reach USD 3.05 Billion in 2026. It is expected to continue growing at a CAGR of 8.16%, reaching USD 4.94 Billion by 2032.

Pneumococcal testing is becoming increasingly important as healthcare systems intensify efforts to detect, monitor, and manage infections caused by Streptococcus pneumoniae, including pneumonia, meningitis, bacteremia, otitis media, and sepsis. The clinical need is reinforced by the World Health Organization’s recognition of pneumonia as a major infectious cause of death among children, while older adults, immunocompromised individuals, and people with chronic cardiopulmonary conditions remain at elevated risk for severe pneumococcal disease. Diagnostic approaches span blood culture, cerebrospinal fluid testing, sputum culture, urinary antigen testing, serotyping, antimicrobial susceptibility testing, and molecular assays such as PCR-based platforms. Demand for accurate pneumococcal diagnostics is shaped by antibiotic stewardship, vaccine impact assessment, outbreak investigation, and surveillance of antimicrobial resistance. As conjugate vaccine programs alter circulating serotypes and reduce vaccine-type disease, laboratories and public health agencies increasingly require sensitive, specific, and timely testing tools to differentiate pneumococcal infection from other respiratory pathogens and guide appropriate treatment decisions.

Transformative Shifts in Pneumococcal Diagnostics

The pneumococcal testing landscape is shifting from conventional culture-dependent workflows toward integrated diagnostic pathways that combine rapid antigen detection, molecular diagnostics, serotype surveillance, and antimicrobial resistance monitoring. Culture remains essential for isolate recovery and susceptibility testing, but its performance can be affected by prior antibiotic exposure and specimen quality. Molecular methods are gaining relevance because they can detect pneumococcal DNA directly from clinical specimens and support faster identification in invasive disease settings. At the same time, expanded respiratory multiplex testing is changing how clinicians evaluate pneumonia and acute respiratory infections by identifying bacterial and viral co-pathogens within a single workflow. Public health priorities are also transforming demand: vaccine introduction and schedule updates require ongoing serotype distribution monitoring, while antimicrobial resistance surveillance depends on reliable laboratory confirmation. These shifts are encouraging laboratories to standardize pre-analytical processes, strengthen quality assurance, and connect diagnostic outputs with clinical decision support and epidemiological reporting systems.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence pneumococcal testing through data interpretation, workflow optimization, syndromic triage, and surveillance analytics rather than replacing core laboratory confirmation. In clinical settings, AI-enabled decision support can help integrate symptoms, radiology findings, inflammatory markers, microbiology results, vaccination status, and risk factors to prioritize testing and guide empiric therapy. In laboratories, machine learning can support image-based colony recognition, flag unusual susceptibility patterns, and optimize test utilization by identifying cases where molecular or antigen testing may add clinical value. For public health agencies, AI can strengthen early warning systems by analyzing laboratory notifications, antimicrobial resistance trends, hospitalization patterns, and genomic surveillance outputs. However, effective use requires validated datasets, transparent performance metrics, bias assessment, cybersecurity safeguards, and clinician oversight. The cumulative impact of artificial intelligence is therefore expected to be strongest where diagnostic data are interoperable, laboratory information systems are modernized, and governance frameworks ensure that automated insights remain clinically accountable and evidence-based.

Key Regional Insights

In North America, pneumococcal testing is supported by mature laboratory networks, high use of respiratory diagnostics, strong invasive pneumococcal disease surveillance, and established adult and pediatric vaccination programs, with the United States and Canada emphasizing antimicrobial resistance monitoring and serotype tracking. Europe benefits from coordinated public health surveillance, national reference laboratories, and broad clinical adoption of microbiology quality standards, while pneumococcal disease monitoring is closely linked with vaccine policy evaluation across diverse healthcare systems. Asia-Pacific presents a mixed but rapidly evolving environment: Japan, Australia, South Korea, China, India, and ASEAN countries are strengthening respiratory infection diagnostics, yet access varies between tertiary centers and primary care settings, particularly in rural and resource-constrained areas. Latin America is advancing laboratory capacity through immunization programs, sentinel surveillance, and regional collaboration, with Brazil and Mexico playing prominent roles in pneumococcal disease monitoring. The Middle East, particularly GCC health systems, shows increasing investment in hospital diagnostics and digital health infrastructure, while Africa faces the highest need for accessible pneumococcal testing due to pneumonia burden, HIV prevalence in some countries, and constraints in laboratory capacity; ongoing improvements in vaccination coverage, specimen referral systems, and point-of-care approaches are central to expanding diagnostic reach.

Key Group Insights

Across ASEAN, pneumococcal testing priorities are shaped by dense urban populations, variable vaccine program maturity, and the need to improve access to rapid respiratory diagnostics beyond major hospitals. GCC countries are focusing on advanced hospital-based diagnostics, antimicrobial stewardship, and surveillance systems aligned with expanding healthcare infrastructure and high levels of cross-border travel. The European Union emphasizes harmonized disease surveillance, laboratory quality standards, vaccine policy assessment, and antimicrobial resistance reporting, making pneumococcal diagnostics a core component of broader infectious disease control. BRICS countries reflect diverse testing realities: China and India are expanding molecular and hospital laboratory capacity, Brazil and South Africa are central to regional infectious disease surveillance, and Russia maintains a strong public health laboratory structure. G7 countries generally demonstrate high diagnostic readiness, extensive reference laboratory capabilities, and robust vaccine impact monitoring, supporting continued innovation in pneumococcal testing algorithms. NATO member states overlap substantially with high-income health systems in North America and Europe, where preparedness planning, respiratory pathogen surveillance, and laboratory interoperability have gained strategic importance following recent global health emergencies.

Key Country Insights

The United States has extensive invasive pneumococcal disease surveillance, broad clinical use of respiratory panels, and strong emphasis on antibiotic stewardship, while Canada combines provincial laboratory systems with national monitoring of serotypes and vaccine impact. Mexico and Brazil are strengthening pneumococcal testing through public immunization programs, pediatric disease surveillance, and expanding laboratory networks. In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain advanced microbiology infrastructure, established vaccination policies, and active antimicrobial resistance programs, while Russia continues to rely on public health laboratories and regional infectious disease surveillance. China is expanding hospital-based molecular diagnostics and respiratory pathogen testing capacity, supported by growing attention to pneumonia management and antimicrobial resistance. India faces a high pneumonia burden and is increasing access to diagnostics through public health initiatives, tertiary care laboratories, and vaccination expansion, though access gaps remain across geographies. Japan, Australia, and South Korea have strong laboratory quality systems, aging populations that increase adult pneumococcal disease relevance, and established surveillance frameworks. Together, these countries illustrate how pneumococcal testing adoption depends on vaccine policy, laboratory infrastructure, reimbursement pathways, clinician awareness, and the ability to connect diagnostic results with treatment and public health action.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize pneumococcal testing strategies that improve diagnostic accuracy, clinical utility, and public health value without adding unnecessary workflow complexity. Key actions include strengthening culture and molecular testing integration, expanding serotype and antimicrobial resistance surveillance, validating assays across relevant specimen types, and improving turnaround time for severe pneumonia, meningitis, and bacteremia cases. Laboratories should invest in staff training, external quality assessment, standardized specimen handling, and interoperability between diagnostic instruments, laboratory information systems, and public health reporting platforms. Healthcare providers should align testing algorithms with vaccination history, disease severity, local resistance patterns, and antibiotic stewardship goals. Policymakers and procurement teams should support equitable access to reliable pneumococcal diagnostics in primary care, emergency departments, pediatric settings, and high-burden regions. Developers of new assays should focus on clinical validation, affordability, ease of use, multiplex compatibility, and differentiation between colonization and invasive disease. Strategic collaboration among clinicians, laboratories, immunization programs, and surveillance authorities will be essential to translate test results into faster care decisions and stronger disease prevention.

Research Methodology

This executive summary is based on a structured review of verified public health, clinical, and laboratory evidence related to pneumococcal disease and diagnostic testing. Sources considered include guidance and surveillance materials from global and national public health agencies, peer-reviewed literature on Streptococcus pneumoniae diagnostics, vaccine impact studies, antimicrobial resistance monitoring publications, and recognized clinical microbiology standards. The analysis focused on diagnostic modalities, clinical use cases, regional testing capacity, public health surveillance needs, vaccine-driven serotype dynamics, and the role of digital and AI-enabled tools in laboratory and epidemiological workflows. Information was evaluated for relevance, recency, consistency across credible sources, and applicability to pneumococcal testing in both high-resource and resource-limited settings. The methodology intentionally excludes market sizing, revenue estimation, market share analysis, and forecasting, concentrating instead on evidence-backed trends, operational implications, and strategic considerations for healthcare stakeholders.

Conclusion

Pneumococcal testing is evolving into a more integrated, surveillance-driven, and clinically actionable field as healthcare systems respond to pneumonia burden, invasive pneumococcal disease, vaccine-related serotype shifts, and antimicrobial resistance. Culture, antigen testing, molecular assays, serotyping, and susceptibility testing each remain important, but their greatest value emerges when they are deployed through well-designed diagnostic algorithms and connected to treatment decisions and public health reporting. Regional differences in laboratory capacity and healthcare access continue to shape adoption, yet the global direction is clear: faster, more reliable, and more interoperable pneumococcal diagnostics are becoming central to respiratory infection management. Artificial intelligence, digital reporting, and genomic surveillance can further enhance impact when implemented with validation and governance. Stakeholders that invest in quality systems, equitable access, antimicrobial stewardship alignment, and vaccine impact monitoring will be better positioned to improve outcomes for patients at risk of pneumococcal disease.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Pneumococcal Testing Market, by Type Of Test
7.1. Introduction
7.2. Culture Based
7.2.1. Automated Culture
7.2.2. Conventional Culture
7.3. Molecular
7.3.1. Digital PCR
7.3.2. Multiplex PCR
7.3.3. Real Time PCR
7.4. Serological
7.5. Pneumococcal Urinary Antigen Test (UAT)
8. Pneumococcal Testing Market, by Sample Type
8.1. Introduction
8.2. Blood
8.3. Urine
8.4. Sputum
8.5. Cerebrospinal Fluid (CSF)
8.6. Pleural Fluid
9. Pneumococcal Testing Market, by Application
9.1. Introduction
9.2. Carrier Screening
9.2.1. Nasopharyngeal Screening
9.2.2. Oropharyngeal Screening
9.3. Diagnosis
9.3.1. Community Acquired Pneumonia
9.3.2. Meningitis
9.4. Surveillance
9.4.1. Antibiotic Resistance Monitoring
9.4.2. Serotype Distribution
9.5. Vaccine Evaluation
10. Pneumococcal Testing Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Public Health Labs
10.5. Reference Labs
11. Pneumococcal Testing Market, by Region
11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa
12. Pneumococcal Testing Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Pneumococcal Testing Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. Becton, Dickinson and Company
15.3. Bio-Rad Laboratories, Inc.
15.4. bioMérieux SA
15.5. Danaher Corporation
15.6. DiaSorin S.p.A.
15.7. Eurofins Scientific SE
15.8. F. Hoffmann-La Roche Ltd
15.9. Hain Lifescience GmbH by Bruker Corporation
15.10. Hologic, Inc.
15.11. Intec Products, Inc.
15.12. Luminex Corporation
15.13. Meridian Bioscience, Inc.
15.14. OpGen Inc.
15.15. QIAGEN N.V.
15.16. Quest Diagnostics Incorporated
15.17. Quidel Corporation
15.18. Sekisui Diagnostics, LLC
15.19. Siemens Healthineers AG
15.20. Thermo Fisher Scientific Inc.
15.21. Trinity Biotech PLC
List of Figures
FIGURE 1. GLOBAL PNEUMOCOCCAL TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PNEUMOCOCCAL TESTING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PNEUMOCOCCAL TESTING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PNEUMOCOCCAL TESTING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PNEUMOCOCCAL TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL PNEUMOCOCCAL TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PNEUMOCOCCAL TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CULTURE BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CULTURE BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CULTURE BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL AUTOMATED CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL AUTOMATED CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL AUTOMATED CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CONVENTIONAL CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CONVENTIONAL CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CONVENTIONAL CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MOLECULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MOLECULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MOLECULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MULTIPLEX PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MULTIPLEX PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MULTIPLEX PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL REAL TIME PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL REAL TIME PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL REAL TIME PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SEROLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SEROLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL SEROLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PNEUMOCOCCAL URINARY ANTIGEN TEST (UAT) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PNEUMOCOCCAL URINARY ANTIGEN TEST (UAT) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PNEUMOCOCCAL URINARY ANTIGEN TEST (UAT) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL SPUTUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL SPUTUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL SPUTUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PLEURAL FLUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PLEURAL FLUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PLEURAL FLUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CARRIER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CARRIER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NASOPHARYNGEAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NASOPHARYNGEAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NASOPHARYNGEAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL OROPHARYNGEAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL OROPHARYNGEAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL OROPHARYNGEAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL COMMUNITY ACQUIRED PNEUMONIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL COMMUNITY ACQUIRED PNEUMONIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL COMMUNITY ACQUIRED PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MENINGITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MENINGITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MENINGITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL SURVEILLANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL SURVEILLANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTIBIOTIC RESISTANCE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTIBIOTIC RESISTANCE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTIBIOTIC RESISTANCE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL SEROTYPE DISTRIBUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL SEROTYPE DISTRIBUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL SEROTYPE DISTRIBUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL VACCINE EVALUATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL VACCINE EVALUATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL VACCINE EVALUATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL PUBLIC HEALTH LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL PUBLIC HEALTH LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL PUBLIC HEALTH LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL REFERENCE LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL REFERENCE LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL REFERENCE LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 124. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 125. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 126. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 127. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 128. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 129. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 130. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 131. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 143. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 144. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 145. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 146. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 147. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 148. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 149. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 150. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 151. AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 154. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 155. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 156. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 157. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 158. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 159. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 160. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 161. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 162. ASEAN PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 164. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 165. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 166. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 167. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 168. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 169. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 170. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 171. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 172. GCC PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 184. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 185. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 186. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 187. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 188. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 189. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 190. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 191. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 192. BRICS PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 194. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 195. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 196. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 197. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 198. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 199. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 200. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 201. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 202. G7 PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 204. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 205. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 206. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 207. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 208. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 209. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 210. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 211. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 212. NATO PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 215. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 216. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 218. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 219. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 224. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 225. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 226. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 227. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 228. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 229. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 230. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 231. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 232. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 233. CANADA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 234. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 235. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 236. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 237. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 238. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 239. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 240. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 241. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 242. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 243. MEXICO PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 244. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 245. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 246. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 247. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 248. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 249. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 250. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 251. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 252. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 253. BRAZIL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 255. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 256. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 264. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 265. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 266. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 267. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 268. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 269. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 270. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 271. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 272. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 273. GERMANY PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 274. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 275. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 276. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 277. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 278. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 279. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 280. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 281. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 282. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 283. FRANCE PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 284. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 285. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 286. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 287. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 288. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 289. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 290. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 291. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 292. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 293. RUSSIA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 294. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 295. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 296. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 297. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 298. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 299. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 300. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 301. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 302. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 303. ITALY PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 304. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 305. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 306. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 307. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 308. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 309. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 310. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 311. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 312. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 313. SPAIN PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 314. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 315. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 316. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 317. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 318. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 319. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 320. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 321. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 322. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 323. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 324. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 325. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 326. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 327. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 328. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 329. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 330. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 331. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 332. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 333. INDIA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 334. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 335. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 336. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 337. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 338. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 339. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 340. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 341. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 342. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 343. JAPAN PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 344. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 345. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 346. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 347. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 348. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 349. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 350. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 351. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 352. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 353. AUSTRALIA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 354. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 355. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
TABLE 356. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
TABLE 357. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
TABLE 358. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 359. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 360. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
TABLE 361. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
TABLE 362. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
TABLE 363. SOUTH KOREA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 364. GLOBAL PNEUMOCOCCAL TESTING MARKET SHARE, BY KEY PLAYER, 2025
TABLE 365. GLOBAL PNEUMOCOCCAL TESTING MARKET, F

Companies Mentioned

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Hain Lifescience GmbH by Bruker Corporation
  • Hologic, Inc.
  • Intec Products, Inc.
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • OpGen Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Quidel Corporation
  • Sekisui Diagnostics, LLC
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC

Table Information

Report AttributeDetails
No. of Pages182
PublishedJuly 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.05 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.94 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Respiratory Infection Diagnostics Market 2025-2029 - Forecasts by Technology, Plex, Place, Product and Region, with Executive and Consultant Guides - Product Image

Respiratory Infection Diagnostics Market 2025-2029 - Forecasts by Technology, Plex, Place, Product and Region, with Executive and Consultant Guides

  • Report
  • 606 Pages
  • Global
From
Respiratory Infection Diagnostics Market - Global Forecast 2026-2032 - Product Image

Respiratory Infection Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Clinical Diagnostics Market - Global Forecast 2026-2032 - Product Image

Clinical Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Body Fluid Collection and Diagnostics - Global Strategic Business Report - Product Image

Body Fluid Collection and Diagnostics - Global Strategic Business Report

  • Report
  • 479 Pages
  • Global
From
Blood Cancer Diagnostics - Global Strategic Business Report - Product Image

Blood Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 372 Pages
  • Global
From

About the Pneumococcal Test Market

The Pneumococcal Test is a diagnostic tool used to detect the presence of Streptococcus pneumoniae, a bacterium that can cause a range of illnesses, including pneumonia, meningitis, and sepsis. The test is typically performed on a sample of blood, sputum, or cerebrospinal fluid, and can be used to diagnose an infection, determine the severity of the infection, and monitor the effectiveness of treatment. The Pneumococcal Test market is a subset of the larger Diagnostics market, which includes a range of tests used to diagnose and monitor a variety of medical conditions. The Pneumococcal Test market is driven by the increasing prevalence of pneumococcal infections, as well as the need for accurate and timely diagnosis and treatment. Some companies in the Pneumococcal Test market include Abbott, Becton Dickinson, Cepheid, DiaSorin, and Roche. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.